Terms: = Endocrine gland cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Treatment
86 results:
1. Identification and validation of an anoikis-related genes signature for prognostic implication in papillary thyroid cancer.
Zhao R; Lu Y; Wan Z; Qiao P; Yang L; Zhang Y; Huang S; Chen X
Aging (Albany NY); 2024 Apr; 16(8):7405-7425. PubMed ID: 38663918
[TBL] [Abstract] [Full Text] [Related]
2. Iron overload increases the sensitivity of endometriosis stromal cells to ferroptosis via a PRC2-independent function of ezh2.
Luo Y; Li L; Hu Q; Zhang Z; Liu F; Peng Y; Zou Y; Chen L
Int J Biochem Cell Biol; 2024 Apr; 169():106553. PubMed ID: 38417568
[TBL] [Abstract] [Full Text] [Related]
3. Drug-induced inhibition of HMGA and ezh2 activity as a possible therapy for anaplastic thyroid carcinoma.
De Martino M; Pellecchia S; Decaussin-Petrucci M; Testa D; Meireles Da Costa N; Pallante P; Chieffi P; Fusco A; Esposito F
Cell Cycle; 2023; 22(23-24):2552-2565. PubMed ID: 38165007
[TBL] [Abstract] [Full Text] [Related]
4. Modulation of ezh2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid cancer.
de Mello DC; Saito KC; Cristovão MM; Kimura ET; Fuziwara CS
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175580
[TBL] [Abstract] [Full Text] [Related]
5. Validation of ezh2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines.
Nakayama H; Saito N; Kasajima R; Suganuma N; Rino Y; Masudo K; Yamazaki H; Toda S; Sekihara K; Iwasaki H; Hoshino D
Anticancer Res; 2023 Mar; 43(3):1073-1077. PubMed ID: 36854530
[TBL] [Abstract] [Full Text] [Related]
6. Differential effects of the LncRNA RNF157-AS1 on epithelial ovarian cancer cells through suppression of DIRAS3- and ULK1-mediated autophagy.
Xu P; Xu S; Pan H; Dai C; Xu Y; Wang L; Cong Y; Zhang H; Cao J; Ge L; Jia X
Cell Death Dis; 2023 Feb; 14(2):140. PubMed ID: 36805591
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of a Novel Covalent ezh2 Inhibitor Based on Tazemetostat Scaffold for the treatment of Ovarian cancer.
Zhang Q; Chen X; Cao J; Yang W; Wan G; Feng Q; Zhou S; Yang H; Wang N; Liu Z; Xiao H; Zhu Y; Yu L
J Med Chem; 2023 Feb; 66(3):1725-1741. PubMed ID: 36692394
[TBL] [Abstract] [Full Text] [Related]
8. The epigenetic factor CHD4 contributes to metastasis by regulating the ezh2/β-catenin axis and acts as a therapeutic target in ovarian cancer.
Wang J; Zhong F; Li J; Yue H; Li W; Lu X
J Transl Med; 2023 Jan; 21(1):38. PubMed ID: 36681835
[TBL] [Abstract] [Full Text] [Related]
9. Genomic Profiling Reveals the Variant Landscape of Sporadic Parathyroid Adenomas in Chinese Population.
Tao X; Xu T; Lin X; Xu S; Fan Y; Guo B; Deng X; Jiao Q; Chen L; Wei Z; Chen C; Yang W; Zhang Z; Yu X; Yue H
J Clin Endocrinol Metab; 2023 Jun; 108(7):1768-1775. PubMed ID: 36611251
[TBL] [Abstract] [Full Text] [Related]
10. Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
Huang TT; Burkett SS; Tandon M; Yamamoto TM; Gupta N; Bitler BG; Lee JM; Nair JR
Oncogene; 2022 Nov; 41(46):5020-5031. PubMed ID: 36224341
[TBL] [Abstract] [Full Text] [Related]
11. FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through ezh2-mediated H3K27me3.
Xiong X; Lai X; Zhang J; Meng Q; Wang P; Qin S; Liu W; Wang Y; Yao Z; Wang D; Li X; Liu Z; Miao H
Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 36000567
[TBL] [Abstract] [Full Text] [Related]
12. SOX8 Affects Tumoral SPARC Expression by Regulating ezh2 to Attenuate Effectiveness of albumin-bound paclitaxel in PDAC.
Yuan S; Xu J; Zhou B; Zhou Y; Lang M; Cao J; Liu Z; Yang S; Gao S; Hao J
Int J Biol Sci; 2022; 18(3):911-922. PubMed ID: 35173526
[TBL] [Abstract] [Full Text] [Related]
13. Dual G9A/ezh2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma.
Spiliopoulou P; Spear S; Mirza H; Garner I; McGarry L; Grundland-Freile F; Cheng Z; Ennis DP; Iyer N; McNamara S; Natoli M; Mason S; Blyth K; Adams PD; Roxburgh P; Fuchter MJ; Brown B; McNeish IA
Mol Cancer Ther; 2022 Apr; 21(4):522-534. PubMed ID: 35131874
[TBL] [Abstract] [Full Text] [Related]
14. Tumor-derived exosomal long noncoding RNA LINC01133, regulated by Periostin, contributes to pancreatic ductal adenocarcinoma epithelial-mesenchymal transition through the Wnt/β-catenin pathway by silencing AXIN2.
Liu Y; Tang T; Yang X; Qin P; Wang P; Zhang H; Bai M; Wu R; Li F
Oncogene; 2021 Apr; 40(17):3164-3179. PubMed ID: 33824474
[TBL] [Abstract] [Full Text] [Related]
15. KDM2B is involved in the epigenetic regulation of TGF-β-induced epithelial-mesenchymal transition in lung and pancreatic cancer cell lines.
Wanna-Udom S; Terashima M; Suphakhong K; Ishimura A; Takino T; Suzuki T
J Biol Chem; 2021; 296():100213. PubMed ID: 33779563
[TBL] [Abstract] [Full Text] [Related]
16. ezh2-mediated lncRNA ABHD11-AS1 promoter regulates the progression of ovarian cancer by targeting miR-133a-3p.
Zhang W; Huang X; Shi J
Anticancer Drugs; 2021 Mar; 32(3):269-277. PubMed ID: 33491971
[TBL] [Abstract] [Full Text] [Related]
17. Downregulation of hsa_circ_0026123 suppresses ovarian cancer cell metastasis and proliferation through the miR‑124‑3p/ezh2 signaling pathway.
Yang X; Wang J; Li H; Sun Y; Tong X
Int J Mol Med; 2021 Feb; 47(2):668-676. PubMed ID: 33416105
[TBL] [Abstract] [Full Text] [Related]
18. Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by ezh2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma.
Han T; Zhuo M; Yuan C; Xiao X; Cui J; Qin G; Wang L; Jiao F
Cancer Biol Med; 2020 Nov; 17(4):953-969. PubMed ID: 33299646
[TBL] [Abstract] [Full Text] [Related]
19. LncRNA STXBP5-AS1 suppresses stem cell-like properties of pancreatic cancer by epigenetically inhibiting neighboring androglobin gene expression.
Chen S; Huang L; Li G; Qiu F; Wang Y; Yang C; Pan J; Wu Z; Chen J; Tian Y
Clin Epigenetics; 2020 Nov; 12(1):168. PubMed ID: 33160411
[TBL] [Abstract] [Full Text] [Related]
20. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.
Borges KS; Pignatti E; Leng S; Kariyawasam D; Ruiz-Babot G; Ramalho FS; Taketo MM; Carlone DL; Breault DT
Oncogene; 2020 Jul; 39(30):5282-5291. PubMed ID: 32561853
[TBL] [Abstract] [Full Text] [Related]
[Next]
